Recursion Pulls In $239M for AI Drug Discovery, Bayer Bets on Fibrosis

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Challenges of Adopting Data Science & AI in Pharma/Biotech
Recursion Screens Protein-Small Molecule Interactions at Vast Scale
What We Really Need is International Women’s Artificial Intelligence Day